You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
石藥集團(01093.HK):"唑來膦酸注射液"獲藥品註冊批件
格隆匯 01-10 17:51

格隆匯1月10日丨石藥集團(01093.HK)宣佈,集團附屬公司石藥集團恩必普藥業有限公司開發的"唑來膦酸注射液(100ml:4mg)"已獲得中華人民共和國國家藥品監督管理局頒發的藥品註冊批件,並視同通過仿製藥質量和療效一致性評價。

唑來膦酸是一種破骨細胞中法尼基焦磷酸合成酶抑制劑,通過對破骨細胞活性的抑制,從而抑制骨重吸收。臨牀與標準抗腫瘤藥物合用,治療實體腫瘤骨轉移患者和多發性骨髓瘤患者的骨胳損害,並可用於治療惡性腫瘤引起的高鈣血癥(HCM)。作為輔助治療的藥物,該產品可減輕腫瘤患者的痛苦。

該產品的獲批將進一步豐富集團的產品組合,並有助於集團在抗腫瘤領域的發展。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account